Table 3 Overview of clinical studies of CAR-NK
From: Chimeric antigen receptor engineered natural killer cells for cancer therapy
Clinical trial identifier | Target | Cancer type | Cell source | Phase | First posted | Current status | Sponsors | Country |
|---|---|---|---|---|---|---|---|---|
NCT02742727 | CD7 | CD7+ R/R leukemia/lymphoma | NK-92 | I, II | 2016 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd | China |
NCT03559764 | BCMA | R/R multiple myeloma | iPSC-NK | I | 2018 | Unknown | Allife Medical Science and Technology Co., Ltd | China |
NCT03940833 | BCMA | Multiple myeloma | NK-92 | I, II | 2019 | Unknown | Asclepius Technology Company Group (Suzhou) Co., Ltd | China |
NCT05008536 | BCMA | Refractory multiple myeloma | CB-NK | I | 2021 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd | China |
NCT05182073 | BCMA | Multiple myeloma | iPSC-NK | I | 2022 | Recruiting | Fate Therapeutics | United States |
NCT05652530 | BCMA | Multiple myeloma | Unknown | I | 2022 | Recruiting | Shenzhen Pregene Biopharma Co., Ltd | China |
NCT00995137 | CD19 | Acute myeloid leukemia | PB-NK | I | 2009 | Completed | St. Jude Children’s Research Hospital | China |
NCT01974479 | CD19 | Acute lymphoblastic leukemia | PB-NK | I | 2013 | Suspended | National University Health System, Singapore | Singapore |
NCT02892695 | CD19 | R/R CD19+ leukemia and lymphoma | NK-92 | I, II | 2016 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd | China |
NCT03056339 | CD19 | B-cell lymphoid malignancies | CB-NK | I, II | 2017 | Recruiting | M.D. Anderson Cancer Center | United States |
NCT03690310 | CD19 | Refractory B-cell lymphoma | iPSC-NK | I | 2018 | Unknown | Allife Medical Science and Technology Co., Ltd | China |
NCT03579927 | CD19 | CD19+Mantle cell lymphoma; recurrent diffuse large B-Cell lymphoma… | CB-NK | I, II | 2018 | Withdrawn | M.D. Anderson Cancer Center | United States |
NCT03824951 | CD19 | Refractory B-cell lymphoma | iPSC-NK | I | 2019 | Unknown | Allife Medical Science and Technology Co., Ltd | China |
NCT04245722 | CD19 | R/R B-cell lymphoma or chronic lymphocytic leukemia | iPSC-NK | I | 2020 | Recruiting | Fate Therapeutics | United States |
NCT04639739 | CD19 | Non-Hodgkin lymphoma | Unknown | I | 2020 | Not yet recruiting | Chongqing Precision Biotech Co., Ltd | China |
NCT04796688 | CD19 | Acute lymphoblastic Leukemia Chronic lymphoblastic leukemia; B-cell lymphoma | Unknown | I | 2021 | Recruiting | Wuhan Union Hospital, China | China |
NCT04796675 | CD19 | Acute lymphocytic leukemia;chronic lymphocytic leukemia; non-Hodgkin lymphoma | CB-NK | I | 2021 | Recruiting | Wuhan Union Hospital, China | China |
NCT04887012 | CD19 | B-cell non-Hodgkin lymphoma | PB-NK | I | 2021 | Recruiting | Second Affiliated Hospital, School of Medicine, Zhejiang University | China |
NCT05020678 | CD19 | non-Hodgkin lymphoma; B-cell acute lymphoblastic leukemia; Large B-cell lymphoma and 7 more B-cell cancer | PB-NK | I | 2021 | Recruiting | Nkarta Inc | United States |
NCT05379647 | CD19 | B-cell lymphoma; B-cell acute lymphoblastic leukemia | unknown | I | 2022 | Recruiting | Zhejiang University | China |
NCT05645601 | CD19 | Adult R/R B-cell hematologic malignancies | unknown | I | 2022 | Recruiting | Beijing JD Biotech Co. LTD | China |
NCT05472558 | CD19 | B-cell non-Hodgkin lymphoma | CB-NK | I | 2022 | Recruiting | Second Affiliated Hospital, School of Medicine, Zhejiang University | China |
NCT05410041 | CD19 | Acute lymphocytic leukemia; chronic lymphocytic leukemia; non-Hodgkin lymphoma | unknown | I | 2022 | Recruiting | Beijing Boren Hospital | China |
NCT05336409 | CD19 | R/R CD19+ B-cell malignancies; indolent non-Hodgkin lymphoma; aggressive non-Hodgkin lymphoma | iPSC-NK | I | 2022 | Recruiting | Century Therapeutics, Inc | United States |
NCT05570188 | CD19 | B-cell lymphoma B-cell leukemia | unknown | I, II | 2022 | withdrawn | Kunming Hope of Health Hospital | China |
NCT05654038 | CD19 | B-cell lymphoblastic leukemia/lymphoma | unknown | I, II | 2022 | Recruiting | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | China |
NCT05673447 | CD19 | diffuse large b cell lymphoma | unknown | I | 2023 | Not yet recruiting | Nanjing Enricnk Biotech Co., Ltd | China |
NCT02892695 | CD19 | R/R CD19+ Leukemia and lymphoma | NK-92 | I, II | 2016 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd | China |
NCT03824964 | CD19/CD22 | Refractory B-cell lymphoma | iPSC-NK | I | 2019 | Unknown | Allife Medical Science and Technology Co., Ltd;Peking University Cancer Hospital & Institute | China |
NCT05667155 | CD19/CD70 | B-cell non-Hodgkin lymphoma | CB-NK | I | 2022 | Recruiting | Second Affiliated Hospital, School of Medicine, Zhejiang University | China |
NCT04023071 | CD20 | Acute myelogenous leukemia; B-cell lymphoma | iPSC-NK | I | 2019 | Recruiting | Fate Therapeutics | United States |
NCT03692767 | CD22 | Refractory B-cell lymphoma | iPSC-NK | I | 2018 | Unknown | Allife Medical Science and Technology Co., Ltd | China |
NCT02944162 | CD33 | R/R acute myeloid leukemia | NK-92 | I, II | 2016 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd | China |
NCT05008575 | CD33 | Acute myeloid leukemia | Unknown | I | 2021 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd | China |
NCT05215015 | CD33 CLL1 | Acute myeloid leukemia | Unknown | I | 2022 | Recruiting | Imbioray (Hangzhou) Biomedicine Co., Ltd | China |
NCT05092451 | CD70 | B-Cell lymphoma; myelodysplastic syndromes (MDS); acute myeloid leukemia | CB-NK | I, II | 2021 | Recruiting | M.D. Anderson Cancer Center | United States |
NCT05574608 | CD123 | Acute myeloid leukemia refractory; acute myeloid leukemia recurrent | Unknown | I | 2022 | Recruiting | Beijing JD Biotech Co. LTD | China |
NCT04614636 | CD38/SLAMF7 | Acute myeloid leukemia; multiple myeloma | iPSC-NK | I | 2020 | Recruiting | Affiliated Hospital to Academy of Military Medical Sciences | China |
NCT03415100 | NKG2D | Solid tumors | PB-NK | I | 2018 | Unknown | Third Affiliated Hospital of Guangzhou Medical University | China |
NCT04623944 | NKG2D ligands | R/R acute myeloid leukemia; refractory myelodysplastic syndromes | PB-NK | I | 2020 | Recruiting | Nkarta Inc | United States |
NCT05247957 | NKG2D | Relapsed or refractory acute myeloid leukemia | CB-NK | I | 2022 | Terminated | Hangzhou Cheetah Cell Therapeutics | China |
NCT05213195 | NKG2D | Metastatic colorectal cancer | unknown | I | 2022 | Recruiting | Zhejiang University | China |
NCT05528341 | NKG2D | R/R solid tumors | NK-92 | I | 2022 | Recruiting | Xinxiang medical university | China |
NCT02839954 | MUC1 | Advanced solid tumors | unknown | I, II | 2016 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd | China |
NCT03383978 | HER2 | Glioblastoma | NK-92 | I | 2017 | Recruiting | Johann Wolfgang Goethe University Hospital | Germany |
NCT03692663 | PSMA | Metastatic Castration-resistant prostate cancer | iPSC-NK | I | 2018 | Recruiting | Allife Medical Science and Technology Co., Ltd | China |
NCT03692637 | Mesothelin | Epithelial ovarian cancer | iPSC-NK | I | 2018 | Unknown | Allife Medical Science and Technology Co., Ltd | China |
NCT03940820 NCT03931720 NCT03941457 | ROBO1 | Solid tumor | Unknown | I, II | 2019 | Unknown | Asclepius Technology Company Group (Suzhou) Co., Ltd | China |
NCT04630769 | CD276 | Ovarian cancer; fallopian tube adenocarcinoma; primary peritoneal cavity cancer | iPSC-NK | I | 2020 | Completed | Masonic Cancer Center, University of Minnesota | United States |
NCT04847466 | PD-L1 | Gastroesophageal junction cancers; advanced head and neck squamous cell carcinoma | NK-92 | II | 2021 | Recruiting | National Cancer Institute (NCI) | United States |
NCT05410717 | Claudin6 | Stage IV ovarian cancer; refractory testis cancer | PB-NK | I, II | 2022 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | China |
NCT05194709 | 5T4 | Advanced solid tumors | Unknown | I | 2022 | Recruiting | Imbioray (Hangzhou) Biomedicine Co., Ltd | China |
NCT05507593 | DLL3 | Small-cell lung cancer | Unknown | I | 2022 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | China |